



**Nath Bio-Genes (I) Ltd.**

(CIN L01110MH1993PLC072842)

25<sup>th</sup> April 2026

The Manager-Listing  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Bandra-Kurla Complex Dalal Street,  
Mumbai-400001

The Manager- Listing  
National Stock Exchange of India Ltd.,  
Exchange Plaza,  
Bandra (E)  
Mumbai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

Sub: Intimation of Board Meeting to consider Audited Financial Results of the Company for the 4<sup>th</sup> quarter and financial year ended 31<sup>st</sup> March 2026.

Ref: Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 29 and 33 of the Listing Regulations 2015, Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Monday, 04<sup>th</sup> May 2026 to approve the following.

1. To consider, approve and take on record Audited Financial Results (Standalone and Consolidated) of the Company for the 4<sup>th</sup> quarter and year ended 31<sup>st</sup> March 2026.
2. To consider recommendation of Dividend for the year 2025-26, if any subject to Approval of shareholders in ensuing AGM.
3. Any other business with the permission of board

The Company has already closed its "Trading Window" under the Code of Conduct for prevention of Insider Trading from 31<sup>st</sup> March 2026 and it will re-open on 06<sup>th</sup> May 2026.

You are requested to take note of the above.

Thanking You.

Yours faithfully,  
For Nath Bio-Genes (India) Limited,

Dhiraj Rathi  
Company Secretary